← All trials
NCT04390113
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2020
- Primary completion
- Apr 15, 2022
- Completion date
- Apr 15, 2022
- First posted
- May 15, 2020
- Last posted
- May 18, 2020
- Enrollment
- 125
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AlloVirLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.